Abstract:Patients with heart failure (HF), particularly those with impaired renal function receiving renin–angiotensin–aldosterone system inhibitors (RAASis), are at risk of hyperkalaemia; when hyperkalaemia is severe, this can have serious clinical consequences. The incidence, prevalence, and risk factors for hyperkalaemia reported in randomized trials of RAASis may not reflect clinical practice due to exclusion of patients with elevated serum potassium (sK+) or severe renal impairment: information on patients managed in routine clinical care is important to understanding the actual burden of hyperkalaemia. This paper reviews the available clinical epidemiology data on hyperkalaemia in HF and considers areas requiring further research. Observational studies published since 2017 that focused on hyperkalaemia, included patients with HF, and had ≥1000 participants were considered. Hyperkalaemia occurrence in HF varied widely from 7% to 39% depending on the setting, HF severity, follow‐up length, and concomitant medications. Rates were lowest in patients with newly diagnosed HF and highest in patients with greater disease severity; comorbidities, such as chronic kidney disease and diabetes, and RAASi use, reflected commonly identified risk factors for hyperkalaemia in patients with HF. Hyperkalaemia was most often mild; however, from the limited data available, persistence of mild hyperkalaemia was associated with an increased risk of mortality and major adverse cardiovascular events. There were also limited data available on the progression of hyperkalaemia. Recurrence was common, occurring in one‐quarter to two‐fifths of hyperkalaemia cases. Despite HF guidelines recommending close monitoring of sK+, 55–93% of patients did not receive appropriate testing before or after initiation of RAASi or in follow‐up to moderate/severe hyperkalaemia detection. Many of the observational studies were retrospective and from a single country. There is a need for international, prospective, longitudinal, observational studies, such as the CARE‐HK in HF study (NCT04864795), to understand hyperkalaemia's prevalence, incidence, and severity; to identify and characterize cases that persist, progress, and recur; to highlight the importance of sK+ monitoring when using RAASi; and to assess the impact of newer HF therapies and potassium binders in clinical practice. Data from both clinical trials and observational studies with adjustments for confounding variables will be needed to assess the contribution of hyperkalaemia to clinical outcomes.

Recommendations for the management of hyperkalemia in the emergency department

Consensus document on the management of hyperkalemia

Acute Hyperkalemia Management in the Emergency Department

Real-World Management of Hyperkalemia in the Emergency Department: an Electronic Medical Record Analysis

Hyperkalemia treatment standard

Hyperkalemia: Pharmacotherapies and Clinical Considerations

Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem

Nouveautés dans la prise en charge de l’hyperkaliémie

Tailoring treatment of hyperkalemia

Hyperkalemia management: a multidisciplinary expert panel's perspective on the role of new potassium binders

Optimising patient care: comprehensive evaluation of inpatient hypokalaemia

Managing hyperkalemia in patients with heart failure on guideline-directed medical therapy: challenges and opportunities

A case of advanced chronic kidney disease with severe hypocalcemia, how to safely manage and dialyze?

Descriptive epidemiological study of hyperkalemia among patients in the emergency department

Hyperkalemia in CKD: an overview of available therapeutic strategies

Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis

Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease

Epidemiology and risk factors for hyperkalaemia in heart failure

Binding Potassium to Improve Treatment With Renin-Angiotensin-Aldosterone System Inhibitors: Results From Multiple One-Stage Pairwise and Network Meta-Analyses of Clinical Trials

Iatrogenic hyperchloremia: An overview in hospitalized patients for pharmacists

Hyperkalemia or Not? A Diagnostic Pitfall in the Emergency Department